Smith Group Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Smith Group Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-73,727	Closed	-$588K	–	470
2013 Q3	$588K	Sell	73,727 -7,600	-9%	-$61.1K	0.02%	189
2013 Q2	$628K	Buy	+81,327	New	+$634K	0.03%	200

Other funds holding PDLI

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

Smith Group Asset Management's PDLI Position: Q4 2013 in Review

Smith Group Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2013, closing a stake of 73,727 shares — an estimated $588K sold.

Smith Group Asset Management first reported a position in PDLI in Q2 2013 and held it in 2 quarters. The position peaked at $628K in Q2 2013. 224 funds tracked by Wall St. Rank hold PDLI as of Q4 2013.

Smith Group Asset Management reported no remaining PDL BioPharma, Inc. position as of Q4 2013 after selling out during the quarter.
Smith Group Asset Management sold 73,727 PDL BioPharma, Inc. shares in Q4 2013, an estimated $588K.
Smith Group Asset Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 2 quarters.
Smith Group Asset Management's PDL BioPharma, Inc. position peaked at $628K in Q2 2013.
224 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2013.

Based on Smith Group Asset Management's 13F filing for Q4 2013, filed 29 Jan 2014.